Loading stock data…
RGC
$29.12-0.10 (-0.34%)
Market ClosedLast close May 1
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Regencell Bioscience Holdings Limited in the Healthcare sector is trading at $29.12. The stock is currently 65% below its 52-week high of $83.60, remaining 40.2% above its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why RGC maintains its current momentum and trend strength. The Whystock Score of 90/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$29.12
Potential Upside
5%
Whystock Fair Value$30.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerati...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$14.00B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-60.89%
Volume
Today's trading volume
59,944
Recent News
Auditor Change Puts Regencell Bioscience Governance And Cash Runway In Focus
Regencell Bioscience Holdings (NasdaqCM:RGC) has changed its independent auditor. The company disclosed the auditor replacement as a material corporate governance event. The change could affect how Regencell approaches financial reporting and internal controls going forward. Regencell Bioscience Holdings operates in the bioscience space, where investor attention often centers on research pipelines, regulatory milestones and funding capacity. In this context, an auditor change is not just an...
Taiwan Semiconductor Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks
During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 87 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Upg
Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now
Regencell Bioscience doesn't have a product yet, and there's no indication that one is on the way.
A Look At Regencell Bioscience Holdings (RGC) Valuation After Department Of Justice Investigation News
Regencell Bioscience Holdings (NasdaqCM:RGC) is under investigation by the U.S. Department of Justice over trading in its ordinary shares and various corporate, financial, and accounting matters, placing legal risk firmly in focus for investors. See our latest analysis for Regencell Bioscience Holdings. The stock has been volatile, with a 1 day share price return of a 4.87% decline and a 7 day decline of 7.91%, yet a 90 day share price return of 49.08%. The 1 year total shareholder return is...
Don't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag
Regencell Bioscience is working on TCM opportunities, but what exactly is TCM?